President-elect Donald Trump and his incoming administration are unlikely to attempt a wholesale restructuring of U.S.

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to ...

Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead ...

At Drexel University’s Graduate School of Biomedical Sciences and Professional Studies, graduate students and active ...